Skip to main content
OpenTrials

Clinical trial condition

Basal Ganglia Diseases

Explore clinical trials studying Basal Ganglia Diseases. Study availability and eligibility vary by location and protocol.

4,064 public trials 752 recruiting studies
Refine in advanced search Browse all conditions

Basal Ganglia Diseases trial results

Completed

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT01474421

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +11 more
Locations
  • Novartis Investigative Site Sacramento, California, United States
  • Novartis Investigative Site Manhasset, New York, United States
  • Novartis Investigative Site Cincinnati, Ohio, United States
  • Novartis Investigative Site Cleveland, Ohio, United States
View all 24 locations
View Trial Details
Completed

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491932

Conditions
Anti-Dyskinesia Agents, Basal Ganglia Diseases, Brain Diseases, +11 more
Locations
  • Novartis Investigative Site Englewood, Colorado, United States
  • Novartis Investigative Site Kansas City, Kansas, United States
  • Novartis Investigative Site Milwaukee, Wisconsin, United States
  • Novartis Investigative Site Innsbruck, Austria
View all 32 locations
View Trial Details
Completed

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01173731

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +16 more
Locations
  • Novartis Investigative Site Sunnyvale, California, United States
  • Novartis Investigative Site Englewood, Colorado, United States
  • Novartis Investigative Site Indianapolis, Indiana, United States
  • Novartis Investigative Site Heidelberg, Victoria, Australia
View all 22 locations
View Trial Details
Completed

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

NCT01092065

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +11 more
Locations
  • The Parkinsons Institute Sunnyvale, California, United States
  • Colorado Neurological Institute Englewood, Colorado, United States
  • Indiana University School of Medicine Indianapolis, Indiana, United States
  • University of Kansas Medical Center - Parkinson's Disease and Movement Disorders Center Kansas City, Kansas, United States
View Trial Details
Completed

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491529

Conditions
Anti-Dyskinesia Agents, Basal Ganglia Diseases, Brain Diseases, +11 more
Locations
  • Novartis Investigative Site Sunnyvale, California, United States
  • Novartis Investigative Site Englewood, Colorado, United States
  • Novartis Investigative Site Tampa, Florida, United States
  • Novartis Investigative Site Kansas City, Kansas, United States
View all 39 locations
View Trial Details
Completed

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01385592

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +10 more
Locations
  • Novartis Investigative Site Sunnyvale, California, United States
  • Novartis Investigative Site Englewood, Colorado, United States
  • Novartis Investigative Site London, Ontario, Canada
  • Novartis Investigative Site Gatineau, Quebec, Canada
View all 28 locations
View Trial Details

Related conditions